Group items tagged

In continuation of the NHS Covid vaccine programme, Covid jabs for five and six-year olds will be available at the local vaccination centres or community pharmacies outside of school hours. Following the recent JCVI guidance that recommended all children between 5 and 11 would benefit from a non-urgent offer of the COVID vaccine, the NHS will send invitations to one million families with five and six-year-olds this week. "Invitations being sent to families this week will set out how easy and convenient it is to take up the offer of a vaccine as part of the NHS COVID vaccination programme by booking through the National Booking Service, or visiting their nearest walk-in site," NHS said. Between April 25 and May 1, there are already more than 33,500 children aged five to 11 booked in for their dose of the life-saving vaccine, with a further 50,000 slots still available. Dr Nikki Kanani, GP and Deputy Lead for the NHS COVID-19 vaccination programme, said: "It is great to see so many families already booked in for their children to receive their Covid vaccine this week, helping to protect themselves against potential future waves of the virus.

The NHS on Sunday (January 30) expanded its Covid-19 vaccination programme to include vulnerable children aged five to 11 years. Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book. Besides, children living with someone immunosuppressed will be eligible to get the first dose of the Covid vaccine in line with advice issued by the Joint Committee on Vaccination and Immunisation (JCVI). According to the NHS there are around 500,000 eligible children in the latest cohort. GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: "We know vaccines give significant protection against severe illness from Covid - including the omicron variant, so it is important that our youngest and most at-risk get protected.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees. The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme. The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.

The NHS on Sunday (January 30) expanded its Covid-19 vaccination programme to include vulnerable children aged five to 11 years. Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book. Additionally, children living with someone immunosuppressed will be eligible to get the first dose of the Covid-19 vaccine in line with advice issued by the Joint Committee on Vaccination and Immunisation (JCVI). According to the NHS, there are around 500,000 eligible children in the latest cohort. GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: "We know vaccines give significant protection against severe illness from Covid - including the omicron variant, so it is important that our youngest and most at-risk get protected.

UK regulator has approved a new age-appropriate formulation of the Pfizer BioNTech Covid-19 vaccine for use in children aged 5 to 11 years old. The new paediatric formulation of Covid vaccine meets the required safety, quality and effectiveness standards, the Medicines and Healthcare products Regulatory Agency (MHRA) announced on Wednesday (December 22). Dr June Raine, MHRA chief executive said that parents and carers can be reassured that this approval has been given after robust review of safety data. These data showed a favourable safety profile for use in 5-11-year olds compared with that seen in other age groups, the regulator said. Raine said: "We have carefully considered all the available data and reached the decision that there is robust evidence to support a positive benefit risk for children in this age group.

The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter. The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2). UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University, analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023. Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader community. The sample will be structured to broadly reflect key population characteristics.

The World Health Organization says it is tracking a few dozen cases of two new sub-variants of the highly transmissible Omicron strain of the coronavirus to assess whether they are more infectious or dangerous. It has added BA.4 and BA.5, sister variants of the original BA.1 Omicron variant, to its list for monitoring. It is already tracking BA.1 and BA.2 - now globally dominant - as well as BA.1.1 and BA.3. The WHO said on Monday (April 11) it had begun tracking them because of their "additional mutations that need to be further studied to understand their impact on immune escape potential". Viruses mutate all the time but only some mutations affect their ability to spread or evade prior immunity from vaccination or infection, or the severity of disease they cause. For instance, BA.2 now represents nearly 94% of all sequenced cases and is more transmissible than its siblings, but the evidence so far suggests it is no more likely to cause severe disease.